 NEW YORK, Aug. 29, 2022 GLOBE NEWSWIRE -- Mesoblast Limited ASX:MSB; Nasdaq:MESO, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2022. 